Summit Therapeutics Inc.
ivonescimab
EGFR-mutated locally advanced or metastatic non-squamous NSCLC post‑TKI therapy
Countdown
130days
FDA decision · Nov 14, 2026
What's at stake
The FDA's approval decision on ivonescimab for EGFR-mutated locally advanced or metastatic non-squamous NSCLC post‑TKI therapy is due Nov 14, 2026. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 8-K
verified 13h ago
“Based upon standard review timelines, if the application is accepted as submitted, we anticipate a decision from the agency by the fourth quarter of 2026.”